Fig. 2From: Guselkumab demonstrated an independent treatment effect in reducing fatigue after adjustment for clinical response—results from two phase 3 clinical trials of 1120 patients with active psoriatic arthritisChanges from baseline in FACIT-Fatigue score through week 52 in a DISCOVER-1 and b DISCOVER-2Back to article page